Clinical Trial Update: Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating Co-artemether (artemether/lumefantrine) for acute uncomplicated Plasmodium falciparum malaria in non-immune travelers, focusing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uncomplicated Plasmodium Falciparum Malaria

Drugs mentioned

• Co-artemether (artemether/lumefantrine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Uncomplicated P. Falciparum Malaria | Phase 4 | Status: COMPLETED